Pulmonx Co. (NASDAQ:LUNG) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Pulmonx Co. (NASDAQ:LUNG) have been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $15.71.

Several research firms have weighed in on LUNG. Lake Street Capital started coverage on Pulmonx in a report on Tuesday, June 4th. They set a “buy” rating and a $12.00 target price on the stock. Piper Sandler reissued an “overweight” rating and issued a $17.00 price objective on shares of Pulmonx in a research note on Wednesday, April 3rd. Finally, Canaccord Genuity Group decreased their target price on Pulmonx from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd.

Pulmonx Price Performance

Shares of LUNG opened at $7.75 on Friday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.14 and a current ratio of 6.95. The firm has a market cap of $300.86 million, a PE ratio of -5.03 and a beta of 0.62. The firm’s 50 day moving average price is $7.09 and its 200 day moving average price is $9.24. Pulmonx has a twelve month low of $5.67 and a twelve month high of $14.84.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, May 1st. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. Pulmonx had a negative net margin of 80.46% and a negative return on equity of 48.09%. The business had revenue of $18.85 million for the quarter, compared to the consensus estimate of $17.54 million. During the same quarter last year, the firm earned ($0.42) EPS. As a group, research analysts expect that Pulmonx will post -1.63 EPS for the current fiscal year.

Insider Transactions at Pulmonx

In related news, insider Geoffrey Beran Rose sold 4,297 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $6.97, for a total transaction of $29,950.09. Following the completion of the sale, the insider now owns 301,203 shares in the company, valued at approximately $2,099,384.91. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, insider Geoffrey Beran Rose sold 4,297 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $6.97, for a total transaction of $29,950.09. Following the completion of the transaction, the insider now directly owns 301,203 shares in the company, valued at $2,099,384.91. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel David Aaron Lehman sold 5,475 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $6.97, for a total transaction of $38,160.75. Following the completion of the sale, the general counsel now owns 209,113 shares in the company, valued at approximately $1,457,517.61. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,140 shares of company stock worth $85,717. Company insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LUNG. Quest Partners LLC bought a new stake in shares of Pulmonx in the fourth quarter valued at about $94,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Pulmonx by 609.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock worth $79,000 after purchasing an additional 7,316 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Pulmonx during the 4th quarter worth approximately $117,000. EntryPoint Capital LLC bought a new stake in shares of Pulmonx during the first quarter valued at approximately $102,000. Finally, Olympiad Research LP acquired a new position in shares of Pulmonx in the fourth quarter valued at $153,000. Institutional investors own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.